Safety and efficacy of tazarotene foam for the treatment of acne vulgaris

Abstract

Background

Tazarotene foam is the first topical retinoid foam approved for the treatment of acne vulgaris.

Objective

To review the safety and efficacy studies of tazarotene foam in the treatment of moderate to severe acne.

Methods

Five Phase I safety studies in normal controls are reviewed and two Phase III safety and efficacy studies in patients with moderate to severe acne are reviewed.

Conclusion

Tazarotene foam, 0.1% was effective in the treatment of moderate to severe acne vulgaris with an acceptable tolerability profile. This treatment provides a cosmetically favorable alternative for topical retinoid therapy.

Keywords:

• tazarotene
• acne
• foam
• topical retinoid

Disclosure

Dr Stein Gold has been a consultant, investigator and/or speaker for Stiefel, Galderma, Allergan, Valeant Pharmaceuticals, Ferndale, Merz, Taro, Ranbaxy. The other author reports no conflicts of interest in this work.